Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.
In stable patients with previous myocardial infarction, left ventricular ejection fraction ≥40%, no heart failure, and no other indication for β-blocker therapy, discontinuation met the non-inferiority criteria for the primary and key secondary endpoints.
Abstract
Background
Many stable patients with chronic coronary syndrome continue β-blocker therapy for years after a myocardial infarction, despite having no clear ongoing indication. Whether β-blockers can be safely discontinued in such patients remains uncertain. The objective of this analysis was to assess the non-inferiority of β-blocker discontinuation versus continuation in patients with previous myocardial infarction and no remaining indication.
Methods
We performed a pooled analysis of individual patient data from the ABYSS and SMART-DECISION randomised trials in stable patients over 6 months after a myocardial infarction with a left ventricular ejection fraction of ≥40% and no heart failure. Non-inferiority was assessed for the composite primary endpoint of all-cause death, myocardial infarction, stroke, or hospitalisation for cardiovascular reasons, and for the key secondary endpoint of all-cause death, myocardial infarction, or hospitalisation for heart failure. Analyses used a one-stage mixed-effects Cox proportional hazards model including trial as a random effect with margins of 1·25 for the primary endpoint and 1·40 for the key secondary endpoint. The review protocol was registered with PROSPERO, number CRD420261299839.
Findings
Among 6238 patients (3698 from ABYSS and 2540 from SMART-DECISION), 3092 were assigned to β-blocker discontinuation and 3146 to continuation. Median time from index myocardial infarction to randomisation was 3·6 years (IQR 1·6-7·5) and median follow-up was 3·0 years (2·3-3·8). The primary endpoint occurred in 532 (17·2%) of 3092 patients in the β-blocker discontinuation group and 500 (15·9%) of 3146 in the continuation group (hazard ratio 1·09 [95% CI 0·97-1·24]; pnon-inferiority=0·016). The key secondary endpoint occurred in 201 (6·5%) of 3092 patients in the discontinuation group and 201 (6·4%) of 3146 patients in the continuation group (1·01 [0·83-1·23]; pnon-inferiority=0·0006). Findings were consistent irrespective of background left ventricular ejection fraction.
Interpretation
In stable patients with previous myocardial infarction, left ventricular ejection fraction ≥40%, no heart failure, and no other indication for β-blocker therapy, discontinuation met the non-inferiority criteria for the primary and key secondary endpoints. Interpretation of the primary endpoint is limited by its hospitalisation-heavy and trial-dependent composition.
Beta-blocker (BB) therapy after myocardial infarction (MI) in patients with reduced left ventricular ejection fraction (LVEF) is well established. However, recent randomised controlled trials (RCTs) in post-MI patients without significantly impaired LVEF have yielded conflicting results. This meta-analysis aimed...
I. F. Arba, A. Primiputri, M. B. A. Paramarta et al.· European Heart Journal, Supp...· 0 citations
In this meta-analysis of randomized clinical trials, beta-blocker use was not associated with a significant reduction in the primary composite outcome or in mortality or reinfarction, and should be interpreted with caution in the context of an overall neutral result.
L. D. Neira-Chunga, D. Moncada-Gutiérrez, G. Vásquez-Tirado et al.· Medicina Intensiva· 0 citations
The modified TRS-2P stratified baseline risk and provided estimates of absolute beta-blocker benefit, supporting further evaluation of individualized, risk-guided treatment after MI in patients with LVEF ≥40%.
H. Caglar, T. Holmager, A. Kristensen et al.· European Heart Journal - Qua...· 0 citations
In contemporary revascularized patients with preserved or mildly reduced EF, β-blocker discontinuation was not associated with a credible increase in death or MACE, whether stopped in the stable phase or the acute-withdrawal phase; the prior harm likely reflects immortal-time bias and inclusion of non-revascularized pa...
Abdul Basit, K. Mahajan, Ashfaq Ahmad et al.· Journal of Saidu Medical Col...· 0 citations
In patients with HFpEF and concomitant AF, beta-blocker therapy is associated with significant reductions in all-cause and cardiovascular mortality and a permissive clinical approach to beta-blocker use is supported, particularly for rate control in those with elevated heart rates.
Shahrukh Mohammed, Khubaib Mohammad Murtafa, Rohit Vondivillu Srinivasan et al.· Irish Journal of Medical Sci...· 0 citations
Among patients with AMI complicated by HF, in-hospital BB use was associated with lower 1-year adverse outcomes risk in HFrEF/HFmrEF, but not in HFpEF.